The pharmacokinetic profile of voriconazole during continuous high-volume venovenous hemofiltration in a critically ill patient

Therapeutic Drug Monitoring

Volumn 30, Issue 1, 2008, Pages 117-119

  Quintard, Hervé ^a,b   Papy, Emmanuelle ^b   Massias, Laurent ^b   Lasocki, Sigismond ^b   Arnaud, Philippe ^b   Desmonts, Jean Marie ^b   Montravers, Philippe ^b  

^a University Hospital of Nice University of Nice Sophia Antipolis   (France)

^b BICHAT HOSPITAL   (France)

Author keywords

Antifungals; Hemofiltration; Pharmacokinetics; Renal failure

Indexed keywords

VORICONAZOLE;

ACUTE KIDNEY FAILURE; AGED; AREA UNDER THE CURVE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA UTILIS; CANDIDIASIS; CASE REPORT; CONTINUOUS HEMOFILTRATION; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECIUM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTENSIVE CARE; MALE; PRIORITY JOURNAL;

AGED; ANTIFUNGAL AGENTS; AREA UNDER CURVE; ASPERGILLOSIS; CRITICAL ILLNESS; FATAL OUTCOME; HALF-LIFE; HEMOFILTRATION; HUMANS; KIDNEY FAILURE, ACUTE; MALE; METABOLIC CLEARANCE RATE; PYRIMIDINES; TRIAZOLES;

EID: 38549162273     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31815c1672     Document Type: Article

References (17)

1. Nolla-Salas J. Candidemia in non neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study group of fungal infection in the ICU. Intensive Care Med. 1997;23:23-30.
2. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;34:563-571.
3. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408-415.
4. Pearson M. Voriconazole: a new triazole antifungal agent. Ann Pharmacother. 2003;37:420-432.
5. Purkins L. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol. 2003;56:10-16.
6. Grootendorst A. High volume hemofiltration improves right ventricular function in endotoxin-induced shock in the pig. Intensive Care Med. 1992;18:235-240.
7. Trotman R. Antibiotic dosing in critically ill patients receiving continuous renal replacement therapy. Clin Infect Dis. 2005;41:1159-1166.
8. Robatel C. Disposition of voriconazole during continuous veno-venous haemofiltration (CVVHDF) in a single patient. J Antimicrob Chemother. 2004;54:269-270.
9. Gage R. A rapid HPLC assay for voriconazole in human plasma J Pharm Biomed Anal. 1998;17:1449-1453.
10. Murayama IN, Nakane T, Shimizu M, et al. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. Biochem Pharmacol. 2007;73:2020-2026.
11. Theuretzbacher IF, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet. 2006;45:649-663.
12. Von Mach JB, Weilemann LS. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. BMC Clin Pharmacol. 2006;18:6.
13. Geist EG, Burhenne J, Mikus G. Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotype. Antimicrob Agents Chemother. 2006;50:3227-3228.
14. Trifilio PG, Pi J, Zook J, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer. 2007;109:1532-1535.
15. Imhof SD, Schanz U, Schwarz U. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly. 2006;135:739-742.
16. Smith SN, Knasinski V, Simmons W, et al. Voriconazole therapeutic drug monitoring. Agents Chemother. 2006;50:1570-1572.
17. Purkins L, Wood N, Ghahramani P, et al. Pharmacokinetics and safety of voriconazole following intravenous to oral dose escalation regimens. Antimicrob Agents Chemother. 2002;46:2546-2553.